Low expression of microRNA-129-5p predicts poor clinical outcome in diffuse large B cell lymphoma (DLBCL)
2013 (English)In: International journal of hematology, ISSN 0925-5710, E-ISSN 1865-3774, Vol. 97, no 4, 465-471 p.Article in journal (Refereed) Published
Diffuse large B cell lymphoma (DLBCL) is a heterogeneous group of B cell lymphomas. MicroRNA expression provides a new and interesting tool for understanding the biology and clinical course of DLBCL. The present study presents microRNA-129-5p expression data from DLBCL patients treated with CHOP or R-CHOP. Patients with low microRNA-129-5p expression had a median survival of 23 months and a significantly shorter overall survival (P = 0.0042) compared to patients with high microRNA-129-5p expression, who had a median survival of 58 months. We also found that patients treated with R-CHOP only and displaying low microRNA-129-5p expression had a significantly shorter overall survival compared to patients with high microRNA-129-5p expression; all such patients were still alive at the time of last follow-up (P = 0.043). No significant difference was found among microRNA-129-5p expression in tumor tissue, the tissue surrounding the tumor, and normal controls. To our knowledge, this is the first report to show that the expression of microRNA-129-5p can affect the clinical outcome of DLBCL patients and that microRNA-129-5p may be involved in the biology of DLBCL development, although larger studies are necessary to confirm this. Further investigations may also help to elucidate the biological role of microRNA-129-5p in DLBCL.
Place, publisher, year, edition, pages
2013. Vol. 97, no 4, 465-471 p.
DLBCL, microRNA-129-5p, Prognosis
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-200079DOI: 10.1007/s12185-013-1303-2ISI: 000317475500005OAI: oai:DiVA.org:uu-200079DiVA: diva2:622710